All Over For AZ's Fasenra In COPD With Second Trial Fail
Executive Summary
It is curtains for AstraZeneca's asthma therapy Fasenra as a COPD treatment after the failure of the TERRANOVA trial, which could be good news for GSK's fellow interleukin-5 drug Nucala, despite the latter's own mixed Phase III data.
You may also be interested in...
AstraZeneca: Don’t Write Off Fasenra In COPD Just Yet
AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.
AZ Explores Orphan Diseases To Boost Fasenra Growth
The company's severe asthma drug Fasenra has demonstrated its effectiveness in a Phase II trial for hypereosinophilic syndrome, a group of rare disorders which can cause progressive organ damage.
AZ Respiratory Head: Fasenra As Add-On Maintenance Can Reduce Exacerbations
AstraZeneca's head of respiratory tells Scrip BORA Phase III data should reinforce and extend physician confidence in Fasenra as a long-term asthma biologic. The drug is also driving wider growth of biologics in asthma.
Need a specific report? 1000+ reports available
Buy Reports